Description
38 consecutive patients undergone ACL one stage revision with BPTB allografts were retrospectively included in this study. The clinical evaluation was based on the IKDC score, Lysholm score, Tegner activity scale and Simple Knee Value score. In addition, we recorded the rate of allograft re-rupture and the rate of post-surgical complications. Patients in our series receiving BPTB allografts showed good to excellent PROMs values at a minimum of 2 years follow-up. The timing for return to play (RTP) was between 6 and 9 months for 19 patients (50.0%), between 9 and 12 months for 7 patients (18.42%) and over 12 months for 12 patients (31.58%). Post-surgical complications were recorded as trivial or minor entity. Although 39.5% of patients experienced a new knee injury, the allograft re-rupture rate was 10.5% (4 out of 38).
In conclusion BPTB allograft in one-stage revision ACL surgery enabled patients to return to sports and to a good quality of life after the final follow-up. Moreover this type of graft has shown to be a safe choice, being burdened by a low rate of post surgical complication and re-rupture risk.
